Accessibility Menu
Mesoblast logo

Mesoblast(ASX) MSB

Market CapA$3.06BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2004)+214%
5 Year+27%
1 Year-0%
1 Month+1%
A$2.36
-5.98%
-0.15Today
Mesoblast last closing stock price
MetricPriceDate
Last closeAUD 2.362026-08-21
Mesoblast stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+6.79%AUD 2.212026-08-14
1 month+0.85%AUD 2.342026-07-22
3 month+11.32%AUD 2.122026-05-22
Year to date-13.24%AUD 2.722025-12-31
1 year-0.42%AUD 2.372025-08-21
3 year+497.47%AUD 0.402023-08-22
5 year+27.22%AUD 1.862021-08-20
Since inception+214.29%AUD 0.752004-12-16

Mesoblast Financials at a Glance

Market Cap

A$3.06BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$65.38M

Net Income (TTM)

-$94.37M

EPS (TTM)

-A$0.11

P/E Ratio

-20.59

Dividend

A$0.00

Beta (Volatility)

-0.13 (Low)

Price

A$2.36

Volume

3,452,079

Open

A$2.48

Previous Close

A$2.36

Daily Range

A$2.34 - A$2.48

52-Week Range

A$1.88 - A$3.31

Estimated Earnings Date

Sep 2, 2026

MSB News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Mesoblast

Mesoblast Limited is an Australian biotechnology company focused on developing innovative regenerative medicine products. Established in 2004, the company operates globally, addressing various medical conditions through its unique mesenchymal lineage cell platform.

Products and Services
  • Remestemcel-L for systemic inflammatory conditions
  • MPC-300-IV targeting rheumatoid arthritis and diabetic nephropathy
  • MPC-25-IC for acute myocardial infarction treatment
Growth Outlook
  • Late-stage trials for Remestemcel-L could lead to significant market opportunities
  • Strategic partnerships enhance commercialization potential in key markets
  • Focus on chronic diseases aligns with growing global healthcare needs
Financial Highlights
  • Recent quarterly revenue of $25.67 million, showing potential for growth
  • Trailing twelve months (TTM) net income margin of -1.44%, indicating ongoing investment in R&D
  • Cash and cash equivalents of $129.58 million, providing operational stability
Mesoblast Limited is positioned in the biotechnology sector, focusing on regenerative medicine. The company’s innovative therapies target critical health issues, including chronic inflammatory conditions and heart diseases. With a robust pipeline and strategic partnerships, Mesoblast aims to capitalize on the growing demand for advanced medical treatments. Recent financial data indicates a commitment to research and development, which may lead to future revenue growth as products progress through clinical trials. The company’s financial stability, highlighted by significant cash reserves, supports ongoing operations and development efforts.
AI Generated • Aug 21, 2026

Industry

Biotechnology

Sector

Health Care

Employees

81

CEO

Silviu Itescu, PhD

Website

www.mesoblast.com

Headquarters

Melbourne, VIC 3000, AU

MSB Financials

Key Financial Metrics (TTM)

Gross Margin

-53.34%

Operating Margin

-223.08%

Net Income Margin

-144.33%

Return on Equity

-16.10%

Return on Capital

-8.61%

Return on Assets

-12.06%

Earnings Yield

-4.86%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

A$3.06BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.30B

Volume

3.45M

Avg. Volume

3.22M

Financials (TTM)

Gross Profit

-$34.88M

Operating Income

-$145.86M

EBITDA

-$64.34M

Operating Cash Flow

-$51.19M

Capital Expenditure

-$1.33M

Free Cash Flow

-$52.52M

Cash & ST Invst.

$129.58M

Total Debt

$135.14M

Mesoblast Performance Analysis

Mesoblast annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-06-30USD 14,078,589N/A
20232023-06-30USD 11,150,512-20.8%
20242024-06-30USD 9,005,531-19.2%
20252025-06-30USD 26,555,246194.9%
Mesoblast sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42025-06-30N/A
Q12025-09-30265.6%
Q22025-12-31N/A
Q32026-03-31N/A
Mesoblast annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-06-30USD -0.18N/A
20232023-06-30USD -0.16-15.1%
20242024-06-30USD -0.14-12.9%
20252025-06-30USD -0.13-4.0%
Mesoblast sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42025-06-30N/A
Q12025-09-3027.2%
Q22025-12-31N/A
Q32026-03-31N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$25.67M

+1526.8%

Gross Profit

-$1.21M

+28.8%

Gross Margin

-4.72%

N/A

Market Cap

A$3.06BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$37.79M

N/A

Employees

81

N/A

Net Income

-$20.08M

+16.2%

EBITDA

-$12.53M

-32.6%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$129.58M

+240.7%

Total Debt

$135.14M

+7.2%

Accounts Receivable

$43.30M

+2465.2%

Inventory

$21.66M

-10.5%

Long Term Debt

$66.02M

-37.8%

Short Term Debt

$69.12M

+247.6%

Return on Assets

-12.06%

N/A

Return on Invested Capital

-22.29%

N/A

Free Cash Flow

-$4.46M

+65.2%

Operating Cash Flow

-$4.11M

+67.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
NEU.AXNeuren Pharmaceuticals Limited
A$22.46-2.94%
SNZ.AXSummerset Group Holdings Limited
A$6.50-1.22%
PYC.AXPYC Therapeutics Limited
A$2.07-5.91%
CU6.AXClarity Pharmaceuticals Ltd
A$2.48-5.34%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.77+0.10%
IBITiShares Bitcoin Trust
$43.68+0.06%
BITOProShares Trust - ProShares Bitcoin ETF
$10.41+0.06%
MARAMara Holdings
$11.26+0.01%

Questions About MSB

What is the current price of Mesoblast?

Mesoblast is trading at A$2.36 per share.

What is the 52-week range for Mesoblast?

Over the past 52 weeks, Mesoblast has traded between A$1.88 and A$3.31.

How much debt does Mesoblast have?

As of the most recent reporting period, Mesoblast reported total debt of $195.56M.

How much cash does Mesoblast have on hand?

Mesoblast reported $246.51M in cash and cash equivalents in its most recent financial results.

What is Mesoblast’s dividend yield?

Mesoblast does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services